Production and Evaluation of a Bivalent Adjuvant Inactivated Vaccine Against Infectious Hematopoietic Necrosis Virus and Infectious Pancreatic Necrosis Virus

Zhen Zhang,Chunyan Guan,Jingzhuang Zhao,Jingnan Lin,Yizhi Shao,Linfang Li,Tongyan Lu,Peng Chen,Yong-An Zhang,Liming Xu
DOI: https://doi.org/10.1016/j.aquaculture.2024.741914
IF: 5.135
2024-01-01
Aquaculture
Abstract:Infectious hematopoietic necrosis virus (IHNV) and infectious pancreatic necrosis virus (IPNV) are important pathogens to salmon and trout worldwide. In this study, we developed a process for producing IHNV and IPNV (genogroup 1, IPNV 1 and genogroup 5, IPNV 5) using EPC and CHSE, respectively, in 750 cm2 rolling bottles. With adjuvant of MontanideTM GEL 02PR, the monovalent vaccines made with produced IHNV, IPNV 1, or IPNV 5 provided strong immune protection against themselves in rainbow trout, RPS of 79.7 % to IHNV at 15 days post vaccination (dpv) and complete inhibition on virus load in vivo to IPNV 1 or IPNV 5 at 30 dpv. The weak cross-protection effect between IPNV 1 and IPNV 5 was characterized, with IPNV 1 providing higher cross-inhibition rates than IPNV 5 when made into monovalent vaccines. Bivalent vaccines, composed of IHNV: IPNV 1: MontanideTM GEL 02PR in 2:7:1 (H2I7) and 3.5:5.5:1 (H3I5), effectively induced immune response and neutralizing antibodies to protect rainbow trout against IHNV, IPNV 1, and IPNV 5. Furthermore, H2I7 was recommended as the appropriate compatibility ratio due to its better performance in most aspects, RPS of 72.2 % and 54.5 % to IHNV at 44 dpv and 74 dpv respectively, along with higher inhibition rate to IPNV 1 and IPNV 5 at 44 and 74 dpv. This study provides references for the production and compatibility process of IHNV and IPNV bivalent inactivated vaccines.
What problem does this paper attempt to address?